Regeneron released encouraging early data showing 100% response rates of Lynozyfic, a T-cell engager, in smoldering multiple myeloma—a precancerous state with high risk of progression. These promising results may expand treatment options and delay disease advancement. Meanwhile, recent preclinical pancreatic cancer studies highlight novel therapeutic targets, including boosting cell surface sugar HSAT to slow tumor growth and metastasis.